BridgeBio Pharma (BBIO) Treasury Shares (2018 - 2026)

BridgeBio Pharma (BBIO) has 7 years of Treasury Shares data on file, last reported at $405.8 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 25.52% year-over-year to $405.8 million; the trailing twelve-month figure through Mar 2026 stood at $405.8 million (up 25.52% YoY), and the FY2025 full-year result was $323.3 million, up 17.55% from the prior year.
• Treasury Shares improved to $405.8 million in Q1 2026, from $323.3 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $10.9 million in Q1 2023 to a low of $6.2 million in Q2 2022.
• A 5-year average of $7.4 million and a median of $6.9 million in 2022 frame the typical range for Treasury Shares.
• Across the five-year window, Treasury Shares surged 5080.86% in 2022 and changed 0.0% in 2023, its largest moves.
• Tracing BBIO's Treasury Shares over 5 years: stood at $275.0 million in 2022, then changed by 0.0% to $275.0 million in 2023, then changed by 0.0% to $275.0 million in 2024, then gained by 17.55% to $323.3 million in 2025, then climbed by 25.52% to $405.8 million in 2026.
• Business Quant data shows BBIO's Treasury Shares at $405.8 million in Q1 2026, $323.3 million in Q4 2025, and $323.3 million in Q3 2025.